Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review
The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.
News
Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies
Karuna Therapeutics files for FDA approval for schizophrenia treatment
ModeX wins $168m BARDA contract to develop viral antibody therapies
Amicus receives FDA approval for Pompe disease therapy
HitGen and SGC enter drug discovery partnership
Deka Biosciences secures $20m to advance product pipeline
Fabre-Kramer gains FDA approval for major depressive disorder therapy
